HAO1 and Nephropathy: After the administration of AAV-SaCas9-Hao1 with a single guide, we showed Hao1-specific editing in a high percentage of hepatocytes, greatly diminishing GO expression, and resulting in the reduction of urine oxalate concentration and prevention of kidney damage and nephrocalcinosis, with no signs of toxicity (Zabaleta et al, 2018b).